Table 2.
Comparisons of clinical and laboratory features among the four treatment groups
| Remission (n = 104) |
Relapse (n = 38) |
|||
|---|---|---|---|---|
| group 1 (n = 76) | group 2 (n = 28) | group 3 (n = 26) | group 4 (n = 12) | |
| Age, years | 46±12 | 49±12 | 48±13 | 39±12 |
| Women | 51 (67.1) | 18 (64.2) | 16 (61.5) | 10 (83.3) |
| Treatment duration, months | 29±22 | 22±20 | 24±21 | 30±28 |
| Follow-up duration, months | 49±26 | 51±26 | 51±21 | 67±26 |
| Follow-up duration since withdrawal of ATD, months | 19±8a | 21±8a | 26±14 | 35±5a |
| History of relapse | 0 | 28 (100) | 10 (38.4) | 8 (66.6) |
| Pretreatment large goiter (>40 g) | 15 (19.7) | 4 (14.3) | 4 (16%) | 1 (7.7) |
| Posttreatment goiter decrease (>30%) | 36 (47.4) | 10 (35.7) | 8 (30.8) | 3 (25) |
| Ophthalmopathy | 7 (9.2) | 4 (14.3) | 4 (16) | 1 (7.7) |
| Pretreatment serum T3, nmol/l | 3.8 (3.3–4.6) | 3.2 (2.2–4.6) | 3.6 (2.6–5.0) | 3.7 (2.6–5.0) |
| Pretreatment serum free T4, pmol/l | 40 (31–45) | 36 (26–45) | 35 (26–53) | 36 (31–50) |
| Pretreatment serum TSH, mU/l | 0.01 (0.01–0.03) | 0.01 (0.01–0.04) | 0.01 (0.01–0.02) | 0.02 (0.01–0.04) |
| Pretreatment serum TRAb, IU/l | 53.3 (24.5–78.2)b | 19.1 (3.3–54.5)b | 21.4 (4.5–57.4) | 37.2 (10.3–58.2) |
| Pretreatment high TRAb (>30 IU/l) | 50 (65.8)c | 10 (35.7)c | 12 (46.2) | 9 (75) |
| Posttreatment serum TRAb, IU/l | 0.7 (0.2–1.7) | 0.5 (0.2–1.6) | 0.7 (0.4–3.7) | 1.6 (0.1–4.4) |
| UIC, μg/l | 453 (176–1,535) | 402 (246–699) | 364 (240–1,070) | 790 (338–925) |
| Urine I/Cr, μg/g Cr | 307 (120–1,029) | 320 (240–627) | 285 (145–1,003) | 315 (151–1,060) |
Data expressed as n (%), means ± SD, or medians (interquartile range).
a
p < 0.001 (group 1 vs. group 4, group 2 vs. group 4).
b
p = 0.009 (group 1 vs. group 2).
c
p = 0.006 (group 1 vs. group 2).